Cardior strengthens patent portfolio of miRNAs for the diagnosis and therapy of heart and kidney diseases
- Key patents acquired from Bayerische Patentallianz
(firmenpresse) - Hanover, Germany, November 1, 2018 - Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has acquired a portfolio of four microRNA (miRNA) patents from Bayerische Patentallianz GmbH (BayPAT). miRNAs are short pieces of ncRNA native to all human cells that act as regulators of gene expression. Cardior Pharmaceuticals has developed a novel class of ncRNA-based therapeutics modulating entire disease pathways to treat diseases with a high unmet medical need.
Among the inventors of the four acquired patents is Prof. Dr. med. Thomas Thum, co-founder and CSO of Cardior. The patents were filed while he was Research Group Leader at Julius-Maximilians-University, Wuerzburg (Germany). Financial terms were not disclosed.
The acquired portfolio comprises three patents on the use of certain miRNAs for the diagnosis and treatment of heart diseases such as cardiac fibrosis and ischemia/ reperfusion injury and one patent covering a number of targets relevant for the diagnosis and treatment of ischemia/reperfusion injuries of the kidney.
She added that Cardior is preparing for the first clinical study of its lead candidate CDR, a synthetic antisense-oligonucleotide inhibitor of a molecular master-switch microRNA, which plays a crucial role in the development of heart failure. CDR aims to halt and reverse heart failure by acting on well-defined cellular pathways and is given by an easy route of administration. Cardior expects to initiate clinical studies in 2019.
###
About Cardior
Cardior Pharmaceuticals is a privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on non-coding RNA (ncRNA). Cardiorfailure. Founded in 2016 based on the work of cardiologist Prof. Dr. Thomas Thum of Hanover Medical School, the Company has raised EUR 15 Mio. from international investors LSP Life Sciences Partners, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech G
Contact Cardior
Claudia Ulbrich / Barbara Gaertner-Rupprecht
Cardior Pharmaceuticals GmbH
Feodor-Lynen-Str.15
30625 Hanover
Germany
Tel: +49 511 33 85 99 30
Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.11.2018 - 05:40 Uhr
Sprache: Deutsch
News-ID 1543422
Anzahl Zeichen: 3281
contact information:
Contact person: Ines-Regina Buth
Town:
Berlin
Phone: 030-23632768
Kategorie:
Healthcare & Medical
Typ of Press Release: Unternehmensinformation
type of sending: Veröffentlichung
Date of sending: 01.11.2018
Anmerkungen:
Diese Pressemitteilung wurde bisher 668 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cardior strengthens patent portfolio of miRNAs for the diagnosis and therapy of heart and kidney diseases
"
steht unter der journalistisch-redaktionellen Verantwortung von
akampion (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
